» Articles » PMID: 29584698

Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2018 Mar 28
PMID 29584698
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

POZ/BTB and AT-hook-containing zinc finger protein 1 (PATZ1) is an emerging cancer-related gene that is downregulated in different human malignancies, including thyroid cancer, where its levels gradually decrease going from papillary thyroid carcinomas (PTC) to poorly differentiated and undifferentiated highly aggressive anaplastic carcinomas (ATC). The restoration of PATZ1 expression in thyroid cancer cells reverted their malignant phenotype by inducing mesenchymal-to-epithelial transition, thus validating a tumor suppressor role for PATZ1 and suggesting its involvement in thyroid cancer progression. Here, we investigated the consequences of the homozygous and heterozygous loss of PATZ1 in the context of a mouse modeling of PTC, represented by mice carrying the oncogene under the thyroid specific control of the thyroglobulin promoter RET/PTC1 (RET/PTC1). The phenotypic analysis of RET/PTC1 mice intercrossed with Patz1-knockout mice revealed that deficiency of both alleles enhanced thyroid cancer incidence in RET/PTC1 mice, but not the heterozygous knockout of the gene. However, both RET/PTC1;Patz1 and RET/PTC1;Patz1 mice developed a more aggressive thyroid cancer phenotype-characterized by higher Ki-67 expression, presence of ATCs, and increased incidence of solid variants of PTC-than that shown by RET/PTC1; Patz1 compound mice. These results confirm that PATZ1 downregulation has a critical role in thyroid carcinogenesis, showing that it cooperates with RET/PTC1 in thyroid cancer progression.

Citing Articles

Binding to the Other Side: The AT-Hook DNA-Binding Domain Allows Nuclear Factors to Exploit the DNA Minor Groove.

Battista S, Fedele M, Secco L, Ingo A, Sgarra R, Manfioletti G Int J Mol Sci. 2024; 25(16).

PMID: 39201549 PMC: 11354804. DOI: 10.3390/ijms25168863.


POZ/BTB and AT hook containing zinc finger 1 (PATZ1) suppresses differentiation and regulates metabolism in human embryonic stem cells.

Huang M, Liao X, Wang X, Qian Y, Zhang W, Chen G Int J Biol Sci. 2024; 20(4):1142-1159.

PMID: 38385086 PMC: 10878140. DOI: 10.7150/ijbs.83927.


PATZ1 in Non-Small Cell Lung Cancer: A New Biomarker That Negatively Correlates with PD-L1 Expression and Suppresses the Malignant Phenotype.

Luca S, Franco R, Napolitano A, Soria V, Ronchi A, Marino F Cancers (Basel). 2023; 15(7).

PMID: 37046851 PMC: 10093756. DOI: 10.3390/cancers15072190.


Efficacy and Safety of Fuzheng Yiqi Kang-Ai Decoction Combined with External Irradiation in the Treatment of Undifferentiated Thyroid Carcinoma and Its Influence on Antiangiogenesis.

Bian L, Zhang J, Wang P J Oncol. 2022; 2022:3589924.

PMID: 35615246 PMC: 9126711. DOI: 10.1155/2022/3589924.


The Transcription Regulator Patz1 Is Essential for Neural Stem Cell Maintenance and Proliferation.

Mancinelli S, Vitiello M, Donnini M, Mantile F, Palma G, Luciano A Front Cell Dev Biol. 2021; 9:657149.

PMID: 33898458 PMC: 8058466. DOI: 10.3389/fcell.2021.657149.


References
1.
Charles R, Silva J, Iezza G, Phillips W, McMahon M . Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res. 2014; 12(7):979-86. PMC: 4635659. DOI: 10.1158/1541-7786.MCR-14-0158-T. View

2.
Chiappetta G, Valentino T, Vitiello M, Pasquinelli R, Monaco M, Palma G . PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration. Oncotarget. 2015; 6(7):5310-23. PMC: 4467151. DOI: 10.18632/oncotarget.2776. View

3.
Leone V, Ferraro A, Schepis F, Federico A, Sepe R, Arra C . The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias. Cancer Lett. 2014; 357(2):535-41. DOI: 10.1016/j.canlet.2014.12.010. View

4.
Yun J, Kim Y, Choe J, Min H, Lee K, Jung Y . Expression of cancer stem cell markers is more frequent in anaplastic thyroid carcinoma compared to papillary thyroid carcinoma and is related to adverse clinical outcome. J Clin Pathol. 2013; 67(2):125-33. DOI: 10.1136/jclinpath-2013-201711. View

5.
Nikiforov Y . RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002; 13(1):3-16. DOI: 10.1385/ep:13:1:03. View